Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Isolation and Generation of Osteoclasts.

Rucci N, Zallone A, Teti A.

Methods Mol Biol. 2019;1914:3-19. doi: 10.1007/978-1-4939-8997-3_1.

PMID:
30729457
2.

Bone Metastasis Pain, from the Bench to the Bedside.

Aielli F, Ponzetti M, Rucci N.

Int J Mol Sci. 2019 Jan 11;20(2). pii: E280. doi: 10.3390/ijms20020280. Review.

3.

Apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC) contributes to osteoblast differentiation and osteogenesis.

Sartoretto S, Gemini-Piperni S, da Silva RA, Calasans MD, Rucci N, Pires Dos Santos TM, Lima IBC, Rossi AM, Alves G, Granjeiro JM, Teti A, Zambuzzi WF.

J Cell Physiol. 2019 Apr;234(4):4140-4153. doi: 10.1002/jcp.27226. Epub 2018 Aug 31.

PMID:
30171612
4.

The Osteoclast in Bone Metastasis: Player and Target.

Maurizi A, Rucci N.

Cancers (Basel). 2018 Jun 27;10(7). pii: E218. doi: 10.3390/cancers10070218. Review.

5.

Regulation of breast cancer induced bone disease by cancer-specific IKKβ.

Marino S, Bishop RT, Capulli M, Sophocleous A, Logan JG, Mollat P, Mognetti B, Ventura L, Sims AH, Rucci N, Ralston SH, Idris AI.

Oncotarget. 2018 Mar 23;9(22):16134-16148. doi: 10.18632/oncotarget.24743. eCollection 2018 Mar 23.

6.

RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development.

Maurizi A, Capulli M, Patel R, Curle A, Rucci N, Teti A.

Bone. 2018 May;110:343-354. doi: 10.1016/j.bone.2018.02.031. Epub 2018 Mar 6.

PMID:
29501587
7.

A Complex Role for Lipocalin 2 in Bone Metabolism: Global Ablation in Mice Induces Osteopenia Caused by an Altered Energy Metabolism.

Capulli M, Ponzetti M, Maurizi A, Gemini-Piperni S, Berger T, Mak TW, Teti A, Rucci N.

J Bone Miner Res. 2018 Jun;33(6):1141-1153. doi: 10.1002/jbmr.3406. Epub 2018 Mar 24.

PMID:
29444358
8.

TRAF2 in osteotropic breast cancer cells enhances skeletal tumour growth and promotes osteolysis.

Peramuhendige P, Marino S, Bishop RT, de Ridder D, Khogeer A, Baldini I, Capulli M, Rucci N, Idris AI.

Sci Rep. 2018 Jan 8;8(1):39. doi: 10.1038/s41598-017-18327-5.

9.

Osteomimicry: How the Seed Grows in the Soil.

Rucci N, Teti A.

Calcif Tissue Int. 2018 Feb;102(2):131-140. doi: 10.1007/s00223-017-0365-1. Epub 2017 Nov 16. Review.

PMID:
29147721
10.

Osteoblast-Derived Extracellular Vesicles Are Biological Tools for the Delivery of Active Molecules to Bone.

Cappariello A, Loftus A, Muraca M, Maurizi A, Rucci N, Teti A.

J Bone Miner Res. 2018 Mar;33(3):517-533. doi: 10.1002/jbmr.3332. Epub 2017 Dec 11.

11.

Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma.

Di Pompo G, Lemma S, Canti L, Rucci N, Ponzetti M, Errani C, Donati DM, Russell S, Gillies R, Chano T, Baldini N, Avnet S.

Oncotarget. 2017 Apr 13;8(33):54478-54496. doi: 10.18632/oncotarget.17091. eCollection 2017 Aug 15.

12.

Non-conventional role of haemoglobin beta in breast malignancy.

Ponzetti M, Capulli M, Angelucci A, Ventura L, Monache SD, Mercurio C, Calgani A, Sanità P, Teti A, Rucci N.

Br J Cancer. 2017 Sep 26;117(7):994-1006. doi: 10.1038/bjc.2017.247. Epub 2017 Aug 3.

13.

Murine models of breast cancer bone metastasis.

Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, Buijs JT, Sterling JA.

Bonekey Rep. 2016 May 11;5:804. eCollection 2016.

14.

Interleukin-1β, lipocalin 2 and nitric oxide synthase 2 are mechano-responsive mediators of mouse and human endothelial cell-osteoblast crosstalk.

Veeriah V, Zanniti A, Paone R, Chatterjee S, Rucci N, Teti A, Capulli M.

Sci Rep. 2016 Jul 19;6:29880. doi: 10.1038/srep29880.

15.

The "soft" side of the bone: unveiling its endocrine functions.

Cappariello A, Ponzetti M, Rucci N.

Horm Mol Biol Clin Investig. 2016 Oct 1;28(1):5-20. doi: 10.1515/hmbci-2016-0009. Review.

PMID:
27107839
16.

The "love-hate" relationship between osteoclasts and bone matrix.

Rucci N, Teti A.

Matrix Biol. 2016 May-Jul;52-54:176-190. doi: 10.1016/j.matbio.2016.02.009. Epub 2016 Feb 26. Review.

PMID:
26921625
17.

Anabolic and Antiresorptive Modulation of Bone Homeostasis by the Epigenetic Modulator Sulforaphane, a Naturally Occurring Isothiocyanate.

Thaler R, Maurizi A, Roschger P, Sturmlechner I, Khani F, Spitzer S, Rumpler M, Zwerina J, Karlic H, Dudakovic A, Klaushofer K, Teti A, Rucci N, Varga F, van Wijnen AJ.

J Biol Chem. 2016 Mar 25;291(13):6754-71. doi: 10.1074/jbc.M115.678235. Epub 2016 Jan 12.

18.

Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2.

Capulli M, Maurizi A, Ventura L, Rucci N, Teti A.

Mol Ther Nucleic Acids. 2015 Sep 1;4:e248. doi: 10.1038/mtna.2015.21.

19.

Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation.

Cappariello A, Paone R, Maurizi A, Capulli M, Rucci N, Muraca M, Teti A.

Biomaterials. 2015 Apr;46:58-69. doi: 10.1016/j.biomaterials.2014.12.033. Epub 2015 Jan 17.

20.

The α2β1 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: a preclinical study.

Rucci N, Capulli M, Olstad OK, Önnerfjord P, Tillgren V, Gautvik KM, Heinegård D, Teti A.

Cancer Lett. 2015 Mar 1;358(1):67-75. doi: 10.1016/j.canlet.2014.12.032. Epub 2014 Dec 18.

PMID:
25529009
21.

Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Rucci N, Sanità P, Delle Monache S, Alesse E, Angelucci A.

World J Clin Oncol. 2014 Aug 10;5(3):335-47. doi: 10.5306/wjco.v5.i3.335. Review.

22.

Lipocalin 2: a new mechanoresponding gene regulating bone homeostasis.

Rucci N, Capulli M, Piperni SG, Cappariello A, Lau P, Frings-Meuthen P, Heer M, Teti A.

J Bone Miner Res. 2015 Feb;30(2):357-68. doi: 10.1002/jbmr.2341.

23.

Prostate cancer and bone: the elective affinities.

Rucci N, Angelucci A.

Biomed Res Int. 2014;2014:167035. doi: 10.1155/2014/167035. Epub 2014 May 28. Review.

24.

Osteoblast and osteocyte: games without frontiers.

Capulli M, Paone R, Rucci N.

Arch Biochem Biophys. 2014 Nov 1;561:3-12. doi: 10.1016/j.abb.2014.05.003. Epub 2014 May 14. Review.

PMID:
24832390
25.

The C-terminal domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss.

Capulli M, Olstad OK, Onnerfjord P, Tillgren V, Muraca M, Gautvik KM, Heinegård D, Rucci N, Teti A.

J Bone Miner Res. 2014 Aug;29(8):1833-46. doi: 10.1002/jbmr.2206.

26.

An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6.

Del Fattore A, Cappariello A, Capulli M, Rucci N, Muraca M, De Benedetti F, Teti A.

Osteoporos Int. 2014 Feb;25(2):681-92. doi: 10.1007/s00198-013-2479-2. Epub 2013 Aug 14.

PMID:
23943168
27.

Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.

Rucci N, Capulli M, Ventura L, Angelucci A, Peruzzi B, Tillgren V, Muraca M, Heinegård D, Teti A.

J Bone Miner Res. 2013 Sep;28(9):1912-24. doi: 10.1002/jbmr.1951.

28.

Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.

Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, Ventura L, Bologna M, Flamini S, Moreschini O, Lidereau R, Ricevuto E, Muraca M, Teti A, Rucci N.

J Bone Miner Res. 2012 Nov;27(11):2387-98. doi: 10.1002/jbmr.1686.

29.

Editorial: bone and immune system cross-talk.

Rucci N, Takayanagi H.

Inflamm Allergy Drug Targets. 2012 Jun;11(3):169. No abstract available.

PMID:
22512479
30.

NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains.

Cardone RA, Greco MR, Capulli M, Weinman EJ, Busco G, Bellizzi A, Casavola V, Antelmi E, Ambruosi B, Dell'Aquila ME, Paradiso A, Teti A, Rucci N, Reshkin SJ.

Mol Biol Cell. 2012 Jun;23(11):2028-40. doi: 10.1091/mbc.E11-11-0911. Epub 2012 Apr 11.

31.

c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling.

Peruzzi B, Cappariello A, Del Fattore A, Rucci N, De Benedetti F, Teti A.

Nat Commun. 2012 Jan 17;3:630. doi: 10.1038/ncomms1651.

PMID:
22252554
32.

Bone cells and the mechanisms of bone remodelling.

Del Fattore A, Teti A, Rucci N.

Front Biosci (Elite Ed). 2012 Jan 1;4:2302-21. Review.

PMID:
22202038
33.

Roles of metalloproteases in metastatic niche.

Rucci N, Sanità P, Angelucci A.

Curr Mol Med. 2011 Nov;11(8):609-22. Review.

PMID:
21707518
34.

Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.

Rufo A, Del Fattore A, Capulli M, Carvello F, De Pasquale L, Ferrari S, Pierroz D, Morandi L, De Simone M, Rucci N, Bertini E, Bianchi ML, De Benedetti F, Teti A.

J Bone Miner Res. 2011 Aug;26(8):1891-903. doi: 10.1002/jbmr.410.

35.

Bone and bone marrow: the same organ.

Del Fattore A, Capannolo M, Rucci N.

Arch Biochem Biophys. 2010 Nov 1;503(1):28-34. doi: 10.1016/j.abb.2010.07.020. Epub 2010 Jul 23. Review.

PMID:
20655867
36.

Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.

Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V.

Cancer Res. 2010 Aug 1;70(15):6150-60. doi: 10.1158/0008-5472.CAN-09-2758. Epub 2010 Jul 14.

37.

Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases.

Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A, Baldini N.

Curr Cancer Drug Targets. 2010 Nov;10(7):649-59.

PMID:
20578992
38.

Osteomimicry: how tumor cells try to deceive the bone.

Rucci N, Teti A.

Front Biosci (Schol Ed). 2010 Jun 1;2:907-15. Review.

PMID:
20515833
39.

The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis.

Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, Capece D, Iansante V, Zazzeroni F, Alesse E, Heinegård D, Teti A.

J Cell Biol. 2009 Nov 30;187(5):669-83. doi: 10.1083/jcb.200906014.

40.
41.

Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.

Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, Raugei G, Calorini L, Rucci N, Teti A, Bologna M, Chiarugi P.

Am J Pathol. 2009 Apr;174(4):1492-503. doi: 10.2353/ajpath.2009.080473. Epub 2009 Mar 5.

42.

Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice.

Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, Cavat F, Rizzoli R, Teti A, Bouxsein ML, Ferrari SL.

J Bone Miner Res. 2009 May;24(5):775-84. doi: 10.1359/jbmr.081237.

43.

A six-gene signature predicting breast cancer lung metastasis.

Landemaine T, Jackson A, Bellahcène A, Rucci N, Sin S, Abad BM, Sierra A, Boudinet A, Guinebretière JM, Ricevuto E, Noguès C, Briffod M, Bièche I, Cherel P, Garcia T, Castronovo V, Teti A, Lidereau R, Driouch K.

Cancer Res. 2008 Aug 1;68(15):6092-9. doi: 10.1158/0008-5472.CAN-08-0436.

44.

Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.

Rucci N, Susa M, Teti A.

Anticancer Agents Med Chem. 2008 Apr;8(3):342-9. Review.

PMID:
18393792
45.

Osteoclast receptors and signaling.

Del Fattore A, Teti A, Rucci N.

Arch Biochem Biophys. 2008 May 15;473(2):147-60. doi: 10.1016/j.abb.2008.01.011. Epub 2008 Jan 24. Review.

PMID:
18237538
46.

Molecular biology of bone remodelling.

Rucci N.

Clin Cases Miner Bone Metab. 2008 Jan;5(1):49-56.

47.

A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts.

Del Fattore A, Fornari R, Van Wesenbeeck L, de Freitas F, Timmermans JP, Peruzzi B, Cappariello A, Rucci N, Spera G, Helfrich MH, Van Hul W, Migliaccio S, Teti A.

J Bone Miner Res. 2008 Mar;23(3):380-91.

48.

Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice.

Nissen-Meyer LS, Jemtland R, Gautvik VT, Pedersen ME, Paro R, Fortunati D, Pierroz DD, Stadelmann VA, Reppe S, Reinholt FP, Del Fattore A, Rucci N, Teti A, Ferrari S, Gautvik KM.

J Cell Sci. 2007 Aug 15;120(Pt 16):2785-95. Epub 2007 Jul 24.

49.

Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system.

De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Ferrari S, Teti A.

Arthritis Rheum. 2006 Nov;54(11):3551-63.

50.

Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio.

Rucci N, Rufo A, Alamanou M, Teti A.

J Cell Biochem. 2007 Feb 1;100(2):464-73.

PMID:
16927271

Supplemental Content

Support Center